Population | Women with HER2-positive breast cancer |
Intervention | Neoadjuvant or adjuvant treatment with subcutaneous trastuzumab |
Control | Neoadjuvant or adjuvant treatment with intravenous trastuzumab |
Outcomes | • Efficacy (overall survival, event-free survival) • Safety: overall risk of adverse events, serious adverse events, discontinuation because of adverse events • Patients’ preferences |
Study design | RCTs, systematic reviews, and meta-analyses |